Modulation of telomerase and signal transduction proteins by Hexyl-ALA-Photodynamic Therapy (PDT) in human doxorubicin resistant cancer cell models

Photodiagnosis and Photodynamic Therapy

Volumn 9, Issue 3, 2012, Pages 243-255

  Chu, Ellie S M ^a   Yow, Christine M N ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

Drug resistance; Hexyl ALA; MAPK; Photodynamic therapy; Telomerase; Uterine sarcoma

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTOPORPHYRIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL MIGRATION; CONFOCAL LASER MICROSCOPY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MODULATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; UTERUS SARCOMA; WILD TYPE;

AMINOLEVULINIC ACID; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SIGNAL TRANSDUCTION; TELOMERASE; TRANSCRIPTION FACTORS; UTERINE NEOPLASMS;

EID: 84865960569     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2011.12.005     Document Type: Article

References (46)

1. Moan J., Peng Q. An outline of the hundred-year history of PDT. Anticancer Res 2003, 23:3591-3600.
2. Ohgari Y., Nakayasu Y., Kitajima S., et al. Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA to the accumulation of protoporphyrin. Biochem Pharmacol 2005, 71:42-49.
3. Casas A., Perotti C., Fukuda H., Rogers L., Butler A.R., Batlle A. ALA and ALA hexyl ester-induced porphyrin synthesis in chemically induced skin tumours: the role of different vehicles on improving photosensitization. Br J Cancer 2001, 85:1794-1800.
4. Shahzidi S., Stokke T., Soltani H., Nesland J.M., Peng Q. Induction of apoptosis by hexaminolevulinate-mediated photodynamic therapy in human colon carcinoma cell line 320DM. J Environ Pathol Toxicol 2006, 25:159-171.
5. Wu R.W.K., Chu E.S.M., Yow C.M.N., Chen J.Y. Photodynamic effects on nasopharyngeal carcinoma (NPC) cells with 5-aminolevulinic acid or its hexyl ester. Cancer Lett 2006, 242:112-119.
6. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
7. Moor A.C. Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B 2000, 57:1-13.
8. Chu E.S., Wu R.W., Yow C.M., Wong T.K., Chen J.Y. The cytotoxic and genotoxic potential of 5-aminolevulinic acid on lymphocytes: a comet assay study. Cancer Chemother Pharmacol 2006, 58:408-414.
9. Chu E.S., Yow C.M., Shi M., Ho R.J. Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. Toxicol Lett 2008, 181:7-12.
10. Wu R.W.K., Yow C.M.N., Wong C.K., Lam Y.H. Photodynamic therapy (PDT) - initiation of apoptosis via activation of stress-activated p38 MAPK and JNK signal pathway in H460 cell lines. Photodiagn Photodyn Ther 2011, 8:254-263.
11. Chu E.S., Wong T.K., Yow C.M. Photodynamic effect in medulloblastoma: downregulation of matrix metalloproteinases and human telomerase reverse transcriptase expressions. Photochem Photobiol Sci 2008, 7:76-83.
12. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
13. Ohyashiki K., Ohyashiki J.H., Toyama K. Technical improvement in determining telomerase activity in hematologic neoplasias: a possibility of single cell determination of telomerase activity. Hum Cell 1996, 9:295-300.
14. Alfonso-De Matte M.Y., Yang H., Evans M.S., Cheng J.Q., Kruk P.A. Telomerase is regulated by c-jun NH2-terminal kinase in ovarian surface epithelial cells. Cancer Res 2002, 62:4575-4578.
15. Campbell L.J., Fidler C., Eagleton H., et al. HTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006, 20:671-679.
16. Chu E.S., Sze S.C., Cheung H.P., et al. Differential effects of anti-metastatic mechanism of Tian-Xian liquid (TXL) and its bioactive fractions on human colorectal cancer models. J Ethnopharmacol 2011, 137:403-413.
17. Kelty C.J., Brown N.J., Reed M.W.R., Ackroyd R. The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci 2002, 1:158-168.
18. Ren Q.G., Wu S.M., Peng Q., Chen J.Y. Comparison of 5-aminolevulinic acid and its hexylester mediated photodynamic action on human hepatoma cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002, 34:650-654.
19. Calzavara-Pinton P.G., Venturini M., Sala R. Photodynamic therapy: update 2006. Part 1: photochemistry and photobiology. J Eur Acad Dermatol Venereol 2007, 21:293-302.
20. Ji Z., Yang G., Vasovic V., et al. Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines. J Photochem Photobiol B 2006, 84:213-220.
21. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 1998, 90:889-905.
22. Oleinick N.L., Morris R.L., Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002, 1:1-21.
23. Assefa Z., Vantieghem A., Declercq W., et al. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J Biol Chem 1999, 274:8788-8796.
24. Klotz L.O., Fritsch C., Briviba K., Tsacmacidis N., Schliess F., Sies H. Activation of JNK and p38 but not ERK MAP kinases in human skin cells by 5-aminolevulinate-photodynamic therapy. Cancer Res 1998, 58:4297-4300.
25. Xue L., He J., Oleinick N.L. Promotion of photodynamic therapy-induced apoptosis by stress kinases. Cell Death Differ 1999, 6:855-864.
26. Dahse R., Mey J. Telomerase in human tumors: molecular diagnosis and clinical significance. Expert Rev Mol Diagn 2001, 1:201-210.
27. Folini M., Zaffaroni N. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies. Curr Pharm Des 2005, 11:1105-1117.
28. Granger M.P., Wright W.E., Shay J.W. Telomerase in cancer and aging. Crit Rev Oncol Hematol 2002, 41:29-40.
29. De Kok J.B., Schalken J.A., Aalders T.W., Ruers T.J., Willems H.L., Swinkels D.W. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 2000, 87:217-220.
30. Lehner R., Enomoto T., McGregor J.A., et al. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol 2002, 84:120-125.
31. Fan Y.D., Liu Z.X., Fang X.L., et al. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res 2005, 11:4331-4337.
32. Chang J.Y. Telomerase: a potential molecular marker and therapeutic target for cancer. J Surg Oncol 2004, 87:1-3.
33. Dahse R., Fiedler W., Ernst G. Telomeres and telomerase: biological and clinical importance. Clin Chem 1997, 43:708-714.
34. Kim N.W. Clinical implications of telomerase in cancer. Eur J Cancer 1997, 33:781-786.
35. Chang J.T., Chen Y.L., Yang H.T., Chen C.Y., Cheng A.J. Differential regulation of telomerase activity by six telomerase subunits. Eur J Biochem 2002, 269:3442-3450.
36. Counter C.M., Meyerson M., Eaton E.N., et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16:1217-1222.
37. Kammori M., Izumiyama N., Hashimoto M., et al. Expression of human telomerase reverse transcriptase gene and protein, and of estrogen and progesterone receptors, in breast tumors: preliminary data from neo-adjuvant chemotherapy. Int J Oncol 2005, 27:1257-1263.
38. Kraemer K., Fuessel S., Kotzsch M., et al. Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment. J Urol 2004, 172:2023-2028.
39. Nakamura M., Masutomi K., Kyo S., et al. Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 2005, 16:859-868.
40. Avilion A.A., Piatyszek M.A., Gupta J., Shay J.W., Bacchetti S., Greider C.W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996, 56:645-650.
41. Blasco M.A., Rizen M., Greider C.W., Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 1996, 12:200-204.
42. Hoang-Vu C., Boltze C., Gimm O., et al. Expression of telomerase genes in thyroid carcinoma. Int J Oncol 2002, 21:265-272.
43. Wu A., Ichihashi M., Ueda M. Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors. Cancer 1999, 86:2038-2044.
44. Koyanagi Y., Kobayashi D., Yajima T., et al. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells. Anticancer Res 2000, 20:773-778.
45. Blackburn E.H. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005, 579:859-862.
46. Woo H.J., Lee S.J., Choi B.T., Park Y.M., Choi Y.H. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol 2007, 82:77-84.